PanArmenian.Net
12 Dec 2019, 17:37 GMT+10
PanARMENIAN.Net - People with advanced HER2-positive breast cancer may soon have some new treatment options after two experimental drugs performed well in clinical trials, Forbes reports.
Around 15-20% of people with breast cancer have cells positive for HER2, meaning that they can be treated with drugs which directly target the HER2 protein, most commonly trastuzumab (also known as Herceptin), often in combination with chemotherapy. Around 80% of HER2-positive patients survive for 10 years or more, with most of these people having no signs of disease after this time. However, many people still experience resistance to treatments and the cancer often spreads, meaning new treatment options are urgently required.
The new research, featuring separate studies of two novel therapies for HER2-positive breast cancer, trastuzumab deruxtecan (T-DXd) and tucatinib, was presented today at the San Antonio Breast Cancer Symposium.
The first new therapy, T-DXd, is an example of a antibody-drug-conjugate treatment, where an antibody (in this case targeted to HER2 called trastuzumab) acts like a grappling hook, attaching to cancer cells and delivering a payload of chemotherapy. The chemotherapy drug in this case stops DNA replication, meaning cancer cells cannot effectively divide. However, it isn't the first HER2-targeting drug of this type. Another, T-DM1, involves trastuzumab combined with a different type of chemotherapy agent, but patients can develop resistance to these drugs, requiring a change of tactics.
The second project involved a global trial called HER2CLIMB and tested a new drug called tucatinib, which targets HER2-positive cells. The trial enrolled over 600 patients with advanced HER2-positive breast cancer, nearly half of whom had their cancer spread to the brain. Tucatinib was used in combination with trastuzumab and capecitabine for half of the patients, whilst the other half was given a placebo instead of tucatinib. For those given tucatinib, 45% of patients were alive after two years, compared to 27% of patients who did not receive the drug as part of their treatment.
Get a daily dose of Herald Globe news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Herald Globe.
More InformationGaza Faces Imminent Famine as Aid Blockade Enters 70th Day, UN Warns The entire population of Gaza is now at critical risk of famine,...
WASHINGTON, D.C.: The Republican-led U.S. House of Representatives has passed a bill to rename the Gulf of Mexico as the Gulf of America,...
HARRISBURG, Pennsylvania: People in Pennsylvania who are 21 or older could soon be allowed to legally buy and use marijuana. The state...
AUSTIN, Texas: Six people in a small Texas county have been charged with serious crimes as part of a growing election investigation...
WASHINGTON, D.C.: The Federal Aviation Administration (FAA) says it is taking urgent steps to fix problems that have caused hundreds...
WASHINGTON, D.C.: This week, U.S. Defense Secretary Pete Hegseth ordered a 20 percent cut in the number of four-star generals and admirals,...
New Delhi [India], May 13 (ANI): Legendary India batter Virat Kohli announced his retirement from Test cricket on Monday, bringing...
New Delhi [India], May 12 (ANI): Indian pace veteran Ishant Sharma, a long-time friend of star India batter Virat Kohli, hailed the...
New Delhi [India], May 12 (ANI): Former Australian captain and Indian head coach hailed star batter Virat Kohli as 'Indian cricket's...
New Delhi [India], May 12 (ANI): Serbian tennis icon Novak Djokovic congratulated star Indian batter Virat Kohli for a remarkable Test...
New Delhi [India], May 12 (ANI): The Board of Control for Cricket in India has informed the ten Indian Premier League (IPL) franchises...
Carlo Ancelotti looks on before the FIFA Intercontinental Cup Qatar 2024 Final match between Real Madrid and Mexico's CF Pachuca at...